Compare CarMax, Inc (KMX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Stryker Corporation — how do they compare? CarMax, Inc trades at $52.72 (market cap $7.64B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 13.9× CarMax, Inc's market cap, and Stryker Corporation pays a 1.27% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Stryker Corporation for 21 Days on average.
| KMX | SYK | |
|---|---|---|
Market Cap | $7.64B | $106.24B |
Volume | 3,610,116 | 2,982,001 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $388.35 |
52-Week Low | $30.88 | $269.75 |
Typical Hold Time | 49 Days | 21 Days |
Enterprise Value | $25.34B | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $52.61, down 1.26% amid bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 25.37 and net margin of 1.06%, while revenue trends downward from $31.9B in 2022 to $26.4B in 2025. Recent Q2 2026 earnings of $1.16 per share beat expectations by 58%, driven by 19.5% revenue growth and improved unit sales under the 'Shift into GEAR' strategy.
The outlook remains cautious with analyst consensus at Hold (62%) and $58.89 price target suggesting 12% upside. Key risks include declining profit margins, high debt load ($18.14B long-term), and competitive pressures. Positive catalysts include continued execution of turnaround strategy and November 3 strategic update.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
